Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Neurocrine Biosciences Inc (NBIX) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance

Neurocrine Biosciences IncTrade
YieldMax Universe Fund of Option Income ETFsTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Neurocrine Biosciences Inc trades at $156.76 (market cap $16.46B), while YieldMax Universe Fund of Option Income ETFs trades at $7.63. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.

NBIXYMAX
Market Cap
$16.46B
Sector
HealthIncome / Options Overlay
52-Week High
$185.50$13.26
52-Week Low
$123.10$7.27
Enterprise Value
$16.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.

YieldMax Universe Fund of Option Income ETFs

YMAX trades at $7.635, down 0.97% on the day, with a bullish technical signal but bearish moving averages. The ETF shows a pattern of weekly dividend distributions, though recent payouts have decreased from $0.15 to $0.06, indicating potential income pressure. Key technical levels show support at $7 and resistance at $8, with RSI suggesting mild overbought conditions.

The outlook for YMAX hinges on its ability to sustain distributions amid cost concerns. Risks include the fund-of-funds fee structure and market volatility. Analyst sentiment is mixed, with some highlighting income appeal but cautioning on expense drag. Upside depends on stable option income generation in varying market regimes.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX

About YieldMax Universe Fund of Option Income ETFs

YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.

Read more on YMAX